JNCI Journal of the National Cancer Institute · 2015 · 17 citations · 16 references
Life SciencesImmunologyOncologyCancer ImmunologySurgical OncologyTumor ImmunologyColorectal CancerImmuno-oncology BiomarkersMalignant NeoplasmsT Cell Responses To TumorsTumor AntigensTumor-infiltrating LymphocytesAntigen-specific T Cell ResponsesColorectal Cancer PrognosisPredictors Of Disease RecurrenceRecurrenceT-cell Responses To Tumor AntigensTumor Antigen RecognitionTumor Stage PrognosisTumor-specific T Cell Activation
Current dogma suggests that tumor-reactive IFN-γ-producing (TH1-type) T-cells are beneficial to patient outcome; however, the clinical consequence of these responses with respect to long-term prognosis in colorectal cancer (CRC) is not understood. Here, we compared the utility of preoperative, peripheral blood-derived IFN-γ(+) T-cell responses specific to carcinoembryonic antigen (CEA), 5T4, or control antigens (n = 64) with tumor staging and clinical details (n = 87) in predicting five-year outcome of CRC patients who underwent resection with curative intent. Although disease recurrence was more likely in patients with stage III tumors, the presence of preoperative, CEA-specific IFN-γ-producing T-cells identified patients at a statistically significantly greater risk of tumor recurrence following surgical resection, irrespective of tumor stage (odds ratio = 5.00, 95% confidence interval = 1.96 to 12.77, two-sided P <.001). Responses to other antigens, including 5T4, did not reflect outcome. Whilst these results initially appear surprising, they could improve prognostication and help redirect adjuvant treatments.
16
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Sergei I. Grivennikov, Kepeng Wang, Daniel Mucida et al. · Nature · 2012 · 1.3K citations · Full text
Medicine, Immunology, Oncology +12
Systemic Therapy for Colorectal Cancer
Jeffrey A. Meyerhardt, Robert J. Mayer · New England Journal of Medicine · 2005 · 1.1K citations
Medicine, Oncology, Pharmacology +17